Hong Kong Respiratory Medicine

 世界胸肺年 Year of the Lung

主辦機構：香港胸肺基金會
支持機構:
  

報名日期 ～ 2010年9月6日
截止報名 ～ 2010年10月6日(以郵戳日期為準)
作品評審 ～ 2010年10月至11月中
公佈結果 ～ 2010年11月20日(請瀏覽本會網頁查核公佈事項, 得獎者亦有專函通知)
頒獎典禮 ～ 2010年12月4日

The late Dr Tse Yuen Man (1968 - 2003); 謝婉雯，金英勇勳章 M.B.G.(追授)（1968年3月31日－2003年5月13日），香港對抗嚴重急性呼吸道症候群(SARS)流行期間為搶救SARS病人而殉職的首位公立醫院醫生。
請按 READ MORE 閲覽比賽章程。

Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann, Ph.D., Mark P. Nicol, Ph.D., Shubhada Shenai, Ph.D., Fiorella Krapp, M.D., Jenny Allen, B.Tech., Rasim Tahirli, M.D., Robert Blakemore, B.S., Roxana Rustomjee, M.D., Ph.D., Ana Milovic, M.S., Martin Jones, Ph.D., Sean M. O'Brien, Ph.D., David H. Persing, M.D., Ph.D., Sabine Ruesch-Gerdes, M.D., Eduardo Gotuzzo, M.D., Camilla Rodrigues, M.D., David Alland, M.D., and Mark D. Perkins, M.D. September 1, 2010 (10.1056/NEJMoa0907847)

Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect.

Peter M. Small, M.D., and Madhukar Pai, M.D., Ph.D. September 1, 2010 (10.1056/NEJMe1008496)

The effective treatment of tuberculosis is a lifesaving intervention. The global scale-up of tuberculosis therapy has averted 6 million deaths over the past 15 years, making it one of the greatest public health interventions of our lifetime.1

Dr José A Caminero MD a b , Giovanni Sotgiu PhD c, Alimuddin Zumla FRCP d, Giovanni Battista Migliori MD e. The Lancet Infectious Diseases, Volume 10, Issue 9, Pages 621 - 629, September 2010

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally thought to have high mortality rates. However, many cases can be treated with the right combination and rational use of available antituberculosis drugs. This Review describes the evidence available for each drug and discusses the basis for recommendations for the treatment of patients with MDR and XDR tuberculosis.